By Uduak Grace Thomas

Accelrys has added a new algorithm to the latest release of its Discovery Studio platform that is expected to be of interest to biotherapeutic developers.

The algorithm, which is the result of a four-year collaboration between the Massachusetts Institute of Technology and Novartis, helps protein engineers identify the size and location of regions on antibodies that are prone to aggregation and then predict mutations to improve the stability of biotherapeutic formulations.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.